Cantor Fitzgerald reiterates overweight rating on Kura Oncology stock

Published 27/06/2025, 13:04
Cantor Fitzgerald reiterates overweight rating on Kura Oncology stock

Investing.com - Cantor Fitzgerald maintained its overweight rating on Kura Oncology (NASDAQ:KURA) stock on Friday. According to InvestingPro data, the stock is currently trading near its 52-week low of $5.41, having declined over 72% in the past year, though analysts maintain a strong bullish consensus with price targets ranging from $8 to $40.

The research firm’s decision comes as investor uncertainty around the market size for menin inhibitors and competitive dynamics among the three players in this space has pressured Kura’s shares. Despite market pressures, the company maintains a healthy financial position with a current ratio of 8.07, indicating strong short-term liquidity. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.

The menin inhibitor market is approaching a significant milestone with potential launches into the NPM1m segment, which represents approximately 30% of acute myeloid leukemia (AML) cases, expected later this year.

These upcoming launches include revumenib from Syndax (NASDAQ:SNDX) and ziftomenib, which could provide more concrete data points to help determine the overall market size.

Cantor Fitzgerald believes these developments may offer "more tangible points to triangulate the market size," potentially addressing some of the uncertainty that has affected Kura’s stock performance.

In other recent news, Kura Oncology has been the subject of several analyst evaluations, focusing on its promising treatment for acute myeloid leukemia (AML), ziftomenib. H.C. Wainwright reiterated its buy rating with a $40 price target, citing favorable safety data from the Phase 1a/1b KOMET-007 trial, which combined ziftomenib with standard chemotherapy. This trial showed high rates of complete response and minimal residual disease negativity. Meanwhile, Cantor Fitzgerald maintained an Overweight rating, highlighting the market potential for menin inhibitors like ziftomenib and noting the pending Prescription Drug User Fee Act (PDUFA) date of November 30, 2025.

Citizens JMP also reaffirmed a Market Outperform rating with a $28 price target, emphasizing the drug’s potential regulatory approval in the fourth quarter of 2025. The firm noted Kura’s strong financial position, with a pro forma cash position of $703.2 million. Additionally, the U.S. Food and Drug Administration (FDA) has accepted Kura’s New Drug Application for ziftomenib in relapsed or refractory NPM1-mutated AML, granting it priority review status. These developments reflect significant advancements in Kura’s clinical programs as it prepares for potential market entry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.